blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2758389

EP2758389 - PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.04.2018
Database last updated on 23.04.2024
FormerThe patent has been granted
Status updated on  05.05.2017
FormerGrant of patent is intended
Status updated on  08.01.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
[2014/31]
Inventor(s)01 / BRUBAKER, Jason
Merck Sharp & Dohme Corp.
33 Avenue Louis Pasteur
Boston, MA 02115-5727 / US
02 / CLOSE, Joshua
Merck Sharp & Dohme Corp.
33 Avenue Louis Pasteur
Boston, MA 02115-5727 / US
03 / SIU, Tony
Merck Sharp & Dohme Corp.
33 Avenue Louis Pasteur
Boston, MA 02115-5727 / US
04 / SMITH, Graham Frank
Merck Sharp & Dohme Corp.
33 Avenue Louis Pasteur
Boston, MA 02115-5727 / US
05 / TORRES, Luis E.
Merck Sharp & Dohme Corp.
33 Avenue Louis Pasteur
Boston, MA 02115-5727 / US
06 / WOO, Hyun Chong
Merck Sharp & Dohme Corp.
33 Avenue Louis Pasteur
Boston, MA 02115-5727 / US
07 / YOUNG, Jonathan R.
Merck Sharp & Dohme Corp.
33 Avenue Louis Pasteur
Boston, MA 02115-5727 / US
08 / WEI, Zhongyong
Pharmaron Beijing, Co., Ltd.
6 Taihe Road
Beijing Economic-Technological Development Area
Beijing 100176 / CN
09 / SHI, Feng
Pharmaron Beijing, Co., Ltd.
6 Taihe Road
Beijing Economic-Technological Development Area
Beijing 100176 / CN
 [2014/31]
Representative(s)Jaap, David Robert
Merck Sharp & Dohme Corp.
120 Moorgate
London, EC2M 6UR / GB
[N/P]
Former [2014/31]Jaap, David Robert
Merck & Co., Inc.
Patent Department
Hertford Road
Hoddesdon, Herts EN11 9BU / GB
Application number, filing date12834277.121.09.2012
[2017/23]
WO2012CN81723
Priority number, dateUS201161537978P22.09.2011         Original published format: US 201161537978 P
[2014/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013041042
Date:28.03.2013
Language:EN
[2013/13]
Type: A1 Application with search report 
No.:EP2758389
Date:30.07.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 28.03.2013 takes the place of the publication of the European patent application.
[2014/31]
Type: B1 Patent specification 
No.:EP2758389
Date:07.06.2017
Language:EN
[2017/23]
Search report(s)International search report - published on:CN28.03.2013
(Supplementary) European search report - dispatched on:EP08.04.2015
ClassificationIPC:C07D401/04, C07D401/14, C07D405/04, C07D405/14, C07D409/04, C07D409/14, C07D413/14, C07D417/14, A61K31/4155, A61K31/4439, A61K31/541, A61P11/00, A61P29/00, A61P35/00
[2014/31]
CPC:
C07D405/08 (EP,US); A61P11/00 (EP); A61P11/06 (EP);
A61P11/08 (EP); A61P19/02 (EP); A61P29/00 (EP);
A61P35/00 (EP); A61P37/00 (EP); A61P37/06 (EP);
A61P37/08 (EP); A61P43/00 (EP); C07D231/38 (EP,US);
C07D401/04 (EP,US); C07D401/06 (EP,US); C07D401/12 (EP,US);
C07D401/14 (EP,US); C07D403/04 (EP,US); C07D403/06 (EP,US);
C07D403/08 (EP,US); C07D403/12 (EP,US); C07D405/04 (EP,US);
C07D405/06 (EP,US); C07D405/12 (EP,US); C07D405/14 (EP,US);
C07D409/04 (EP,US); C07D409/12 (EP,US); C07D413/12 (EP,US);
C07D413/14 (EP,US); C07D417/14 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/31]
TitleGerman:PYRAZOLCARBOXAMIDE ALS JANUSKINASEINHIBITOREN[2014/31]
English:PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS[2014/31]
French:CARBOXAMIDES DE PYRAZOLE COMME INHIBITEURS DE LA JANUS KINASE[2014/31]
Entry into regional phase22.04.2014National basic fee paid 
22.04.2014Search fee paid 
22.04.2014Designation fee(s) paid 
22.04.2014Examination fee paid 
Examination procedure22.04.2014Examination requested  [2014/31]
29.10.2015Amendment by applicant (claims and/or description)
15.04.2016Despatch of a communication from the examining division (Time limit: M04)
24.08.2016Reply to a communication from the examining division
09.01.2017Communication of intention to grant the patent
25.04.2017Fee for grant paid
25.04.2017Fee for publishing/printing paid
25.04.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  15.04.2016
Opposition(s)08.03.2018No opposition filed within time limit [2018/20]
Fees paidRenewal fee
08.09.2014Renewal fee patent year 03
08.09.2015Renewal fee patent year 04
08.09.2016Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.09.2012
AL07.06.2017
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
MK07.06.2017
PL07.06.2017
PT07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IE21.09.2017
LU21.09.2017
MT21.09.2017
BE30.09.2017
IS07.10.2017
[2020/34]
Former [2020/28]HU21.09.2012
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
MK07.06.2017
PL07.06.2017
PT07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IE21.09.2017
LU21.09.2017
MT21.09.2017
BE30.09.2017
IS07.10.2017
Former [2019/51]HU21.09.2012
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
MK07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IE21.09.2017
LU21.09.2017
MT21.09.2017
BE30.09.2017
IS07.10.2017
Former [2019/46]HU21.09.2012
AT07.06.2017
CY07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IE21.09.2017
LU21.09.2017
MT21.09.2017
BE30.09.2017
IS07.10.2017
Former [2019/31]HU21.09.2012
AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IE21.09.2017
LU21.09.2017
MT21.09.2017
BE30.09.2017
IS07.10.2017
Former [2018/43]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IE21.09.2017
LU21.09.2017
MT21.09.2017
BE30.09.2017
IS07.10.2017
Former [2018/39]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IE21.09.2017
LU21.09.2017
BE30.09.2017
IS07.10.2017
Former [2018/34]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IE21.09.2017
LU21.09.2017
IS07.10.2017
Former [2018/29]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
MC07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/25]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SI07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/21]AT07.06.2017
CZ07.06.2017
DK07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/11]AT07.06.2017
CZ07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
PL07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SK07.06.2017
SM07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
IS07.10.2017
Former [2018/10]AT07.06.2017
CZ07.06.2017
EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
RO07.06.2017
RS07.06.2017
SE07.06.2017
SK07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2018/09]EE07.06.2017
FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
RS07.06.2017
SE07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2017/50]FI07.06.2017
HR07.06.2017
LT07.06.2017
LV07.06.2017
RS07.06.2017
SE07.06.2017
BG07.09.2017
NO07.09.2017
GR08.09.2017
Former [2017/49]FI07.06.2017
HR07.06.2017
LT07.06.2017
NO07.09.2017
GR08.09.2017
Documents cited:Search[A]WO2010014453  (MERCK & CO INC [US], et al) [A] 1-15 * example -; claim - *;
 [A]WO2009114512  (INCYTE CORP [US], et al) [A] 1-15 * example -; claim 1 *;
 [A]  - KISS R ET AL, "Recent developments on JAK2 inhibitors: a patent review", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, (20100401), vol. 20, no. 4, doi:10.1517/13543771003639436, ISSN 1354-3776, pages 471 - 495, XP001539996 [A] 1-15 * figure 15 *

DOI:   http://dx.doi.org/10.1517/13543771003639436
International search[A]WO2008132502  (ASTRAZENECA AB [SE], et al);
 [A]WO2011028685  (INCYTE CORP [US], et al);
 [A]WO2011112662  (INCYTE CORP [US], et al);
 [A]WO2010135650  (INCYTE CORP [US], et al);
 [A]WO2011075334  (PFIZER [US], et al)
by applicantWO2010014453
 US4256108
 US4166452
 US4265874
    - K. GHORESCHI; A. LAURENCE; J. J. O'SHEA, IMMUNOL. REV., (2009), vol. 228, page 273
    - J. J. O'SHEA; M. PESU; D. C. BORIE; P. S. CHANGELIAN, NAT. REV. DRUG DISCOV., (2004), vol. 3, page 555
    - Y. MINEGISHI ET AL., IMMUNITY, (2006), vol. 25, page 745
    - O. BDEL-WAHAB, CUR . OPIN. HEMATOL., (2011), vol. 18, page 117
    - K. GHORESCHI ET AL., IMMUNOL. REV., (2009), vol. 228, page 273
    - A. QUINTAS-CARDAMA; H. KANTARJIAN; J. CORTES; S. VERSTOVSEK, NAT. REV. DRUG DISCOV., (2011), vol. 10, page 127
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.